DelveInsight’s ‘Non-small Cell Lung Cancer Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Non-small cell lung cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Non-small cell lung cancer pipeline domain.
To know more about the NSCLC Market report offerings, click here: NSCLC Market Insight
Key Takeaways from the Non-small Cell Lung Cancer Pipeline Report
Request a sample and discover the recent breakthroughs happening NSCLC pipeline landscape in @ Non-small Cell Lung Cancer Pipeline Report
Non-small Cell Lung Cancer Overview
About 85% of all cases of lung cancer are non-small-cell lung cancer (NSCLC), which includes all epithelial lung cancers besides small-cell lung cancer (SCLC). NSCLC tumors come in three different varieties: a) Adenocarcinoma begins in cells that produce mucus and other substances inside air sacs, frequently in the outer regions of your lungs. It is the most prevalent form of lung cancer in people under 45 who smoke, nonsmokers, and both.
The common NSCLC symptoms include chest pain, wheezing, weight loss, shortness of breath, coughing up blood, and others. Several imaging tests such as X-ray, MRI, PET Scans, CT Scans, and others are used for NSCLC diagnosis. Apart from imaging tests, other tests used for NSCLC diagnosis include sputum cytology, bronchoscopy, and mediastinoscopy.
Non-small Cell Lung Cancer Pipeline Analysis: Drug Profile
Datopotamab deruxtecan: Daiichi Sankyo
Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Datopotamab deruxtecan is one of three leading ADCs in Daiichi Sankyo’s oncology pipeline and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is made up of a humanized anti-TROP2 IgG13 monoclonal antibody developed in collaboration with Sapporo Medical University, which is linked to several topoisomerases I inhibitor payloads, an exatecan derivative via tetrapeptide-based cleavable linkers.
MRTX849: Mirati Therapeutics
Adagrasib (MRTX849) is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized for long-term target inhibition, which may be important in treating KRASG12C-mutated cancers because the KRASG12C protein regenerates every 24-48 hours. Adagrasib is being tested in patients with advanced KRASG12C-mutated solid tumors, such as NSCLC, colorectal cancer, and pancreatic cancer, as a monotherapy and in combination with other anti-cancer therapies.
Non-small Cell Lung Cancer Therapies and Key Companies
Learn more about the NSCLC emerging pipeline therapies @Non-small Cell Lung Cancer Clinical Trials
Non-small Cell Lung Cancer Pipeline Therapeutics Assessment
Scope of the Non-small Cell Lung Cancer Pipeline Report
Dive deep into rich insights for NSCLC emerging therapies and assessment, visit @ Non-small Cell Lung Cancer Emerging Therapies
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Overview
4.
Pipeline Therapeutics
5.
Late Stage Products (Phase III)
6.
Mid Stage Products (Phase II)
7.
Early Stage Products (Phase I/II)
8.
Preclinical Stage Products
9.
Discovery Stage Products
10.
Therapeutic Assessment
11.
Inactive Products
12.
Collaborations Assessment- Licensing / Partnering / Funding
13.
Unmet Needs
14.
Market Drivers and Barriers
15.
Appendix
16.
About DelveInsight
For further information on the NSCLC current pipeline therapeutics, reach out @ Non-small Cell Lung Cancer Therapeutics Assessment
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight